Survival in Patients With De Novo Metastatic Prostate Cancer
Menée à partir de données des registres américains des cancers et du registre des vétérans portant sur 73 763 patients atteints d'un cancer de la prostate métastatique hormono-sensible, cette étude analyse l'évolution de la survie globale entre 2000 et 2019
Overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) has improved in clinical trials over the last 20 years.1,2 It is unclear whether new treatments have translated to improvements in survival rates in clinical practice. We sought to quantify trends in OS among patients with newly diagnosed de novo (synchronous) mHSPC in 2 national registries in the United States: the Surveillance, Epidemiology, and End Results 17 (SEER) registry database and the Veterans Health Administration (VHA) registry database.